348 related articles for article (PubMed ID: 36468859)
1. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Coronavirus Entry
Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
[TBL] [Abstract][Full Text] [Related]
3. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
6. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
8. Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein.
Li H; Cheng C; Shi S; Wu Y; Gao Y; Liu Z; Liu M; Li Z; Huo L; Pan X; Liu S; Song G
Eur J Med Chem; 2022 Aug; 238():114426. PubMed ID: 35551037
[TBL] [Abstract][Full Text] [Related]
9. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy.
Santopolo S; Riccio A; Santoro MG
Biochem Biophys Res Commun; 2021 Jan; 538():80-87. PubMed ID: 33303190
[TBL] [Abstract][Full Text] [Related]
10. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics daptomycin interacts with S protein of SARS-CoV-2 to promote cell invasion of Omicron (B1.1.529) pseudovirus.
Cao X; Huang L; Tang M; Liang Y; Liu X; Hou H; Liang S
Virulence; 2024 Dec; 15(1):2339703. PubMed ID: 38576396
[TBL] [Abstract][Full Text] [Related]
12. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike.
Freidel MR; Armen RS
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793593
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
[TBL] [Abstract][Full Text] [Related]
14. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
15. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
16. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
[TBL] [Abstract][Full Text] [Related]
18. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
19. Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro.
Mao B; Le-Trilling VTK; Wang K; Mennerich D; Hu J; Zhao Z; Zheng J; Deng Y; Katschinski B; Xu S; Zhang G; Cai X; Hu Y; Wang J; Lu M; Huang A; Tang N; Trilling M; Lin Y
Emerg Microbes Infect; 2022 Dec; 11(1):483-497. PubMed ID: 34989664
[No Abstract] [Full Text] [Related]
20. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
